Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Down 48.7% in May

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) saw a significant decrease in short interest in May. As of May 15th, there was short interest totaling 57,617 shares, a decrease of 48.7% from the April 30th total of 112,316 shares. Approximately 1.3% of the company’s stock are short sold. Based on an average daily volume of 186,884 shares, the short-interest ratio is currently 0.3 days.

Galmed Pharmaceuticals Trading Down 2.5%

Galmed Pharmaceuticals stock traded down $0.02 during mid-day trading on Monday, hitting $0.74. 188,870 shares of the company’s stock were exchanged, compared to its average volume of 1,870,922. The stock has a market cap of $4.03 million, a P/E ratio of -0.57 and a beta of 0.73. Galmed Pharmaceuticals has a 1-year low of $0.41 and a 1-year high of $2.34. The stock has a 50 day moving average of $0.62 and a two-hundred day moving average of $0.74.

Hedge Funds Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Two Sigma Investments LP bought a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned about 1.28% of Galmed Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 76.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.